Category Press Releases

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize 3D Cell Culture in Drug Discovery

Inventia Life Science Unveils RASTRUM™ Allegro to Transform 3D Cell Culture in Drug Discovery and Disease Research Inventia Life Science, a leader in 3D cell culture technologies, has announced the launch of RASTRUM™ Allegro, a revolutionary platform that enhances drug…

Read MoreInventia Life Science Launches RASTRUM™ Allegro to Revolutionize 3D Cell Culture in Drug Discovery

Genentech’s Itovebi Demonstrates Survival Benefit in HR-Positive Advanced Breast Cancer

Genentech Announces Positive OS Results for Itovebi in Advanced HR-Positive Breast Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced positive topline results from the Phase III INAVO120 study investigating the combination of Itovebi™…

Read MoreGenentech’s Itovebi Demonstrates Survival Benefit in HR-Positive Advanced Breast Cancer

Cannabis Pharmaceuticals Market 2024-2034: Focus on Sativex, Cesamet, Marinol, Epidiolex – ResearchAndMarkets.com

Cannabis Pharmaceuticals Market 2024-2034: Focus on Sativex, Cesamet, Marinol, Epidiolex – ResearchAndMarkets.com The global cannabis pharmaceuticals market, valued at USD 3.46 billion in 2023, is expected to experience remarkable growth, reaching USD 380.77 billion by 2034. This expansion is forecasted…

Read MoreCannabis Pharmaceuticals Market 2024-2034: Focus on Sativex, Cesamet, Marinol, Epidiolex – ResearchAndMarkets.com

Salubris Biotherapeutics Reports Positive Interim Data from Phase 2 Heart Failure Trial of JK07

Salubris Biotherapeutics Announces Positive Interim Data from Phase 2 Trial of JK07 in Heart Failure Salubris Biotherapeutics a clinical-stage biotechnology company focused on developing innovative biologic therapies, has announced promising interim data from its Phase 2 clinical trial of JK07…

Read MoreSalubris Biotherapeutics Reports Positive Interim Data from Phase 2 Heart Failure Trial of JK07

Poxel to Gain Increased Royalties from Sumitomo Pharma for TWYMEEG Sales in Japan

Poxel Achieves Milestone with TWYMEEG® Sales in Japan, Secures Royalties and Sales-Based Payments Poxel, a clinical-stage biopharmaceutical company focused on innovative treatments for chronic serious diseases with metabolic pathophysiology—including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders—has announced a significant…

Read MorePoxel to Gain Increased Royalties from Sumitomo Pharma for TWYMEEG Sales in Japan

MIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available

MIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available Otsuka Pharmaceutical and Ai-BrainScience Inc. have announced the launch of MIREVO®, a pioneering neuropsychological testing program designed to support medical treatment for dementia. As of January 1, 2025, MIREVO® has…

Read MoreMIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available